HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017 – GlobeNewswire (press release)
|
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
GlobeNewswire (press release) For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin lymphoma (NHL) patients has been described. Data analysis pointed to immune programs which may facilitate or modulate anti-tumor … |
The Indian Express |
New gene therapy may ‘turn off’ asthma
The Indian Express New gene therapy may ‘turn off’ asthma. The findings showed that the single treatment may give life-long protection from asthma as well as those who have severe allergies to peanuts, bee venom, shell fish and other substances by de-sensitising the … Gene therapy could wipe immune memory and “turn off” severe allergiesNew Atlas Now, A New Gene Therapy Can “Turn Off” Asthma and Food AllergiesNDTV Food New gene therapy may ‘turn off’ asthma – The Economic TimesEconomic Times Times of India –Zee News –BSI bureau (press release) all 17 news articles » |
|
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor …
PR Newswire (press release) In a study presented today at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, the world’s premier oncology event, researchers at Poseida used its proprietary gene editing tools to create a universal donor CAR–T cell therapy that … |
|
Chinese cell therapy effective in small multiple myeloma trial
Reuters The study of 35 patients tested a chimeric antigen receptor T–cell (CAR-T) therapy developed by China’s Nanjing Legend Biotech Co. The drug candidate, known as LCAR-B38M, targets a protein called BCMA found on cancerous blood plasma cells – the … |
|
Bluebird is pretty chirpy about its anti-BCMA CAR–T therapy results
MedCity News You know you’re on to something worthwhile when your study leader can’t quite hold back the tears when presented with the final data. That was the case with Bluebird Bio’s first major clinical trial for its experimental anti-BCMA CAR–T cell therapy in … |
|
ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T …
Business Wire (press release) ACEA’s xCELLigence RTCA instrument can monitor this cancer cell killing process in real-time without the use of labels so it provides a means of assessing CAR T cell potency under conditions that are of maximal physiological relevance. Dr. Prasad S. |